Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):737–45. https://doi.org/10.1016/S2352-3026(20)30251-9.

Article  Google Scholar 

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. https://doi.org/10.1056/NEJMoa2034577.

Article  CAS  PubMed  Google Scholar 

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16. https://doi.org/10.1056/NEJMoa2035389.

Article  CAS  PubMed  Google Scholar 

Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396(10267):1979–93. https://doi.org/10.1016/S0140-6736(20)32466-1.

Article  PubMed  Google Scholar 

Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of Single-Dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–201. https://doi.org/10.1056/NEJMoa2101544.

Article  CAS  PubMed  Google Scholar 

Ghione P, Gu JJ, Attwood K, Torka P, Goel S, Sundaram S, et al. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies. Blood. 2021;138(9):811–4. https://doi.org/10.1182/blood.2021012443.

Article  CAS  PubMed  Google Scholar 

Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Byrne F, et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nat Cancer. 2021;2:1321–37. https://doi.org/10.1038/s43018-021-00274-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165–73. https://doi.org/10.1182/blood.2021011568.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dabkowska A, Domka K, Firczuk M. Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells. Front Immunol. 2024;15:1363102. https://doi.org/10.3389/fimmu.2024.1363102.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Casan JML, Wong J, Northcott MJ, Opat S. Anti-CD20 monoclonal antibodies: reviewing a revolution. Hum Vaccin Immunother. 2018;14(12):2820–41. https://doi.org/10.1080/21645515.2018.1508624.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Byrne F, et al. Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nat Cancer. 2021;2(12):1305–20. https://doi.org/10.1038/s43018-021-00275-9.

Article  CAS  PubMed  Google Scholar 

Ollila TA, Lu S, Masel R, Zayac A, Paiva K, Rogers RD, et al. Antibody response to COVID-19 vaccination in adults with hematologic malignant disease. JAMA Oncol. 2021;7(11):1714–6. https://doi.org/10.1001/jamaoncol.2021.4381.

Article  PubMed  PubMed Central  Google Scholar 

Buttiron Webber T, Provinciali N, Musso M, Ugolini M, Boitano M, Clavarezza M, et al. Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment. Eur J Cancer. 2021;159:105–12. https://doi.org/10.1016/j.ejca.2021.09.030.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shroff RT, Chalasani P, Wei R, Pennington D, Quirk G, Schoenle MV, et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nat Med. 2021;27(11):2002–11. https://doi.org/10.1038/s41591-021-01542-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ständige, Impfkommission. Beschluss der STIKO Zur 11. Aktualisierung der COVID-19-Impfempfehlung. Epid Bull. 2021;39:3–10. https://doi.org/10.25646/9087.

Article  Google Scholar 

Ständige, Impfkommission. Beschluss der STIKO Zur 18. Aktualisierung der COVID-19-Impfempfehlung. Epid Bull. 2022;7:3–18. https://doi.org/10.25646/9735.

Article  Google Scholar 

Al Hajji Y, Taylor H, Starkey T, Lee LYW, Tilby M. Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic review. Br J Cancer. 2022;127(10):1827–36. https://doi.org/10.1038/s41416-022-01951-y.

Article  PubMed  PubMed Central  Google Scholar 

Fattizzo B, Rampi N, Barcellini W. Vaccinations in hematological patients in the era of target therapies: lesson learnt from SARS-CoV-2. Blood Rev. 2023;60:101077. https://doi.org/10.1016/j.blre.2023.101077.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herishanu Y, Rahav G, Levi S, Braester A, Itchaki G, Bairey O, et al. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood. 2022;139(5):678–85. https://doi.org/10.1182/blood.2021014085.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Greenberger LM, Saltzman LA, Gruenbaum LM, Xu J, Reddy ST, Senefeld JW, et al. Anti-spike T-cell and antibody responses to SARS-CoV-2 mRNA vaccines in patients with hematologic malignancies. Blood Cancer Discov. 2022;3(6):481–9. https://doi.org/10.1158/2643-3230.BCD-22-0077.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shields AM, Venkatachalam S, Paneesha S, Ford M, Sheeran T, Kelly M, et al. Vaccine efficacy after rituximab exposure: first interim analysis of virtue project on behalf of West Midlands research consortium, UK. Blood. 2021;138(Supplement 1):196.

Article  CAS  Google Scholar 

Avivi I, Luttwak E, Saiag E, Halperin T, Haberman S, Sarig A, et al. BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses. Br J Haematol. 2022;196(6):1329–33. https://doi.org/10.1111/bjh.18029.

Article  CAS  PubMed  Google Scholar 

Shapiro LC, Thakkar A, Campbell ST, Forest SK, Pradhan K, Gonzalez-Lugo JD, et al. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. Cancer Cell. 2022;40(1):3–5. https://doi.org/10.1016/j.ccell.2021.11.006.

Article  CAS  PubMed  Google Scholar 

Bedognetti D, Ansaldi F, Zanardi E, Durando P, Sertoli MR, Massucco C, et al. Seasonal and pandemic (A/H1N1 2009) MF-59-adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens. Blood. 2012;120(9):1954–7. https://doi.org/10.1182/blood-2012-06-438689.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lim SH, Stuart B, Joseph-Pietras D, Johnson M, Campbell N, Kelly A, et al. Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. Nat Cancer. 2022;3(5):552–64. https://doi.org/10.1038/s43018-022-00364-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang LM, Costales C, Ramanathan M, Bulterys PL, Murugesan K, Schroers-Martin J, et al. Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: an observational cohort study. J Clin Virol. 2022;153:105217. https://doi.org/10.1016/j.jcv.2022.105217.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nishikubo M, Shimomura Y, Yamamoto R, Yoshioka S, Maruoka H, Nasu S, et al. Humoral and cellular respons